Pilot study of Biomarkers for predicting effectiveness of ramosetron in diarrhea‐predominant irritable bowel syndrome: expression of S100A10 and polymorphisms of TPH1

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2982|27|1|82-91

ISSN： 1350-1925

Source： NEUROGASTROENTEROLOGY & MOTILITY (ELECTRONIC), Vol.27, Iss.1, 2015-01, pp. : 82-91

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes

By Bleser Scott  

Current Medical Research and Opinion, Vol. 27, Iss. 3, 2011-03 ,pp. : 503-512

Informa Healthcare

Access to resources Recommend Favorite

Alosetron: an effective treatment for diarrhea-predominant irritable bowel syndrome

By Harris Lucinda A   Chang Lin  

Women's Health, Vol. 3, Iss. 1, 2007-01 ,pp. : 15-27

Future Medicine

Access to resources Recommend Favorite

A Randomized Clinical Trial of Berberine Hydrochloride in Patients with Diarrhea‐Predominant Irritable Bowel Syndrome

By  

PHYTOTHERAPY RESEARCH, Vol. 29, Iss. 11, 2015-11 ,pp. : 1822-1827

John Wiley & Sons Inc

Access to resources Recommend Favorite

Increased serum levels of lipopolysaccharide and antiflagellin antibodies in patients with diarrhea‐predominant irritable bowel syndrome

By  

NEUROGASTROENTEROLOGY & MOTILITY (ELECTRONIC), Vol. 27, Iss. 12, 2015-12 ,pp. : 1579-1586

John Wiley & Sons Inc

Access to resources Recommend Favorite

Small intestinal bacterial overgrowth as an uncommon cause of false positive lactose hydrogen breath test among patients with diarrhea‐predominant irritable bowel syndrome in Asia

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 30, Iss. 6, 2015-06 ,pp. : 995-1000

John Wiley & Sons Inc

Access to resources Recommend Favorite